RSS   Newsletter   Contact   Advertise with us

Targovax appoints Damian Marron as chairman

Christian Fernsby | Oslo, Norway | April 3, 2020
Damian MarronTargovax, a clinical stage biotechnology company, announces that its nomination committee has nominated Damian Marron for election as chairman of the board.
Mr. Marron is an experienced non-executive director, corporate advisor and life science executive with a successful track record of value creation through public and venture capital financing, portfolio planning, M&A, licensing agreements as well as R&D collaborations, both as an executive and in advisory roles.

Mr. Marron has notably specialized in immuno-oncology, cell therapy and orphan diseases.

Mr. Marron is currently Non-Executive Director at Bone Therapeutics a clinical stage, regenerative medicine company listed on Euronext and Resolys Bio, a private, late pre-clinical US startup.

He is also Head of Biopharma with Treehill Partners, a global pure-play healthcare advisory firm.

Mr. Marron has formerly been Chair of the Board of PepGen Ltd and the CEO at Agalimmune Ltd, TxCell SA, Cytheris SA, and Trophos SA.